<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.3390/vetsci2040456vetsci-02-00456 : Review Efficacy of Antiviral Drugs against Feline" exact="Immunodeficiency" post="Virus HartmannKatrin*WoodingAnitaBergmannMichèle SpargerEllen (Liz)Academic EditorSykesJaneAcademic Editor[], anitaschwartz@hotmail.comn.bergmann@medizinische-kleintierklinik.de *Author to"/>
 <result pre="conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). Abstract Feline" exact="immunodeficiency" post="virus (FIV) is one of the most common infectious"/>
 <result pre="Feline immunodeficiency virus (FIV) is one of the most common" exact="infectious" post="agents affecting cats worldwide .FIV and human immunodeficiency virus"/>
 <result pre="most common infectious agents affecting cats worldwide .FIV and human" exact="immunodeficiency" post="virus (HIV) share many properties: both are lifelong persistent"/>
 <result pre="cats have measurable immune suppression, which sometimes progresses to an" exact="acquired" post="immunodeficiency syndrome. A transient initial state of infection is"/>
 <result pre="have measurable immune suppression, which sometimes progresses to an acquired" exact="immunodeficiency" post="syndrome. A transient initial state of infection is followed"/>
 <result pre="suppression, which sometimes progresses to an acquired immunodeficiency syndrome. A" exact="transient" post="initial state of infection is followed by a long"/>
 <result pre="to an acquired immunodeficiency syndrome. A transient initial state of" exact="infection" post="is followed by a long latent stage with low"/>
 <result pre="by a long latent stage with low virus replication and" exact="absence of" post="clinical signs. In the terminal stage, both viruses can"/>
 <result pre="terminal stage, both viruses can cause severe immunosuppression. Thus, FIV" exact="infection" post="in cats has become an important natural model for"/>
 <result pre="in cats has become an important natural model for studying" exact="HIV infection" post="in humans, especially for evaluation of antiviral compounds. Of"/>
 <result pre="cats has become an important natural model for studying HIV" exact="infection" post="in humans, especially for evaluation of antiviral compounds. Of"/>
 <result pre="1. Introduction FIV can induce immunosuppression, which predisposes cats to" exact="secondary" post="infections, stomatitis, neuropathies, and tumors. FIV does not directly"/>
 <result pre="neuropathies, and tumors. FIV does not directly cause severe clinical" exact="disease" post="in most infected cats. Thus, FIV-infected cats can live"/>
 <result pre="most important strategy for managing FIV-infected cats is treatment of" exact="secondary" post="infections. In cats with recurrent infections despite aggressive management,"/>
 <result pre="FIV-infected cats is treatment of secondary infections. In cats with" exact="recurrent" post="infections despite aggressive management, additional treatment with antiviral drugs"/>
 <result pre="cats is treatment of secondary infections. In cats with recurrent" exact="infections" post="despite aggressive management, additional treatment with antiviral drugs (e.g.,"/>
 <result pre="plerixafor and/or zidovudine) can be considered. Cats with no identifiable" exact="secondary" post="diseases or with secondary disease that has been treated"/>
 <result pre="be considered. Cats with no identifiable secondary diseases or with" exact="secondary" post="disease that has been treated successfully might still suffer"/>
 <result pre="considered. Cats with no identifiable secondary diseases or with secondary" exact="disease" post="that has been treated successfully might still suffer from"/>
 <result pre="an option. Antiviral compounds interfere with certain steps in the" exact="viral" post="replication cycle. Based upon steps targeted, the drugs can"/>
 <result pre="covers the most common drugs used for treatment of FIV" exact="infection" post="(Table A1): reverse transcriptase inhibitors (RTIs), which inhibit the"/>
 <result pre="the retroviral enzyme reverse transcriptase (RTIs); drugs that inhibit other" exact="viral" post="enzymes, such as DNA or RNA polymerases, thereby interfering"/>
 <result pre="replication or with proteinases necessary for splitting precursor proteins during" exact="viral" post="assembly (nucleotide synthesis inhibitors); drugs that target viral entry"/>
 <result pre="proteins during viral assembly (nucleotide synthesis inhibitors); drugs that target" exact="viral" post="entry by binding to specific receptors that the virus"/>
 <result pre="virus necessary for the fusion process, or by interfering with" exact="viral" post="uncoating (receptor homologues/antagonists) [4,6]; drugs that inhibit integration by"/>
 <result pre="inhibiting the retroviral enzyme integrase (integrase inhibitors); drugs that inhibit" exact="viral" post="replication by inhibiting the retroviral enzyme protease (protease inhibitors);"/>
 <result pre="are produced [5,8,9]. NARTIs are accepted as false substrates by" exact="viral" post="enzymes as well as by cellular enzymes, which is"/>
 <result pre="[12] and became the first drug approved for treatment of" exact="HIV infection" post="[13]. The anti-FIV activity of zidovudine has been assessed"/>
 <result pre="and became the first drug approved for treatment of HIV" exact="infection" post="[13]. The anti-FIV activity of zidovudine has been assessed"/>
 <result pre="responsible for resistance [10]. In vivo, zidovudine can reduce plasma" exact="viral" post="load, improve the immunologic and clinical status of FIV-infected"/>
 <result pre="and prolong life expectancy [16]. In placebo-controlled trials, zidovudine improved" exact="stomatitis" post="and increased the CD4/CD8 ratio in naturally FIV-infected cats."/>
 <result pre="RT, but also cellular polymerases, and this can lead to" exact="bone marrow suppression." post="Regular blood cell counts are necessary during zidovudine treatment"/>
 <result pre="blood cell counts are necessary during zidovudine treatment because non-regenerative" exact="anemia" post="is a common side effect [28]. Cats with bone"/>
 <result pre="non-regenerative anemia is a common side effect [28]. Cats with" exact="bone marrow suppression" post="should not be treated with zidovudine. Most FIV-infected cats"/>
 <result pre="hematocrit drops below 20%, discontinuation of treatment is recommended, and" exact="anemia" post="usually resolves within a few days. Other side effects"/>
 <result pre="drug effective against HIV. It was approved for treatment of" exact="HIV infection" post="in 1994, but in recent years has been replaced"/>
 <result pre="effective against HIV. It was approved for treatment of HIV" exact="infection" post="in 1994, but in recent years has been replaced"/>
 <result pre="cross-resistant to several other antivirals, including zidovudine, have been detected." exact="Resistance" post="is caused by a single-point mutation in the RT-encoding"/>
 <result pre="didanosine, but treatment contributed to the development of antiretroviral toxic" exact="neuropathy" post="[39]. 2.4. Lamivudine Lamivudine (2R,cis-4-amino-l-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 3TC) is also an"/>
 <result pre="with a high-dose zidovudine/lamivudine combination, which protected some cats from" exact="infection" post="when treatment was started before virus inoculation. However, zidovudine/lamivudine"/>
 <result pre="zidovudine/lamivudine treatment showed no anti-FIV activity in chronically infected cats." exact="Severe" post="side effects, including fever, anorexia, and marked hematologic changes,"/>
 <result pre="an oral formulation (bis-POM PMEA) approved for the treatment of" exact="chronic hepatitis" post="B. Adefovir belongs to the acyclic nucleoside phosphonates, in"/>
 <result pre="oral formulation (bis-POM PMEA) approved for the treatment of chronic" exact="hepatitis" post="B. Adefovir belongs to the acyclic nucleoside phosphonates, in"/>
 <result pre="cats received placebo. There was no decrease in proviral or" exact="viral" post="loads in treated cats, and treated cats developed a"/>
 <result pre="Tenofovir Currently, the only approved NtARTi for the treatment of" exact="HIV infection" post="is tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir"/>
 <result pre="Currently, the only approved NtARTi for the treatment of HIV" exact="infection" post="is tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir"/>
 <result pre="agent and for the treatment of some tumors, such as" exact="prostate cancer" post="[58]. It also has an inhibitory effect on the"/>
 <result pre="and for the treatment of some tumors, such as prostate" exact="cancer" post="[58]. It also has an inhibitory effect on the"/>
 <result pre="of retroviruses and has also been used in humans with" exact="HIV infection" post="[59]. Suramin inhibits RT by interacting with the template-primer"/>
 <result pre="retroviruses and has also been used in humans with HIV" exact="infection" post="[59]. Suramin inhibits RT by interacting with the template-primer"/>
 <result pre="classified as an NNRTI [60]. Suramin is effective against feline" exact="leukemia" post="virus (FeLV) in vivo [61,62], and thus, could potentially"/>
 <result pre="nausea and anaphylactic shock as immediate reactions during administration and" exact="peripheral neuritis" post="leading to palmar-plantar hyperesthesia, photophobia, skin reactions, agranulocytosis, hemolytic"/>
 <result pre="and anaphylactic shock as immediate reactions during administration and peripheral" exact="neuritis" post="leading to palmar-plantar hyperesthesia, photophobia, skin reactions, agranulocytosis, hemolytic"/>
 <result pre="peripheral neuritis leading to palmar-plantar hyperesthesia, photophobia, skin reactions, agranulocytosis," exact="hemolytic anemia," post="and destruction of the adrenal cortex as later side"/>
 <result pre="with FeLV infection, the major adverse effects of suramin were" exact="transient" post="vomiting and anorexia [61]. 5. Nucleotide Synthesis Inhibitors Nucleotide"/>
 <result pre="interfere with the exchange of pyrophosphate from deoxynucleoside triphosphate during" exact="viral" post="replication by binding to RT or DNA polymerase, thereby"/>
 <result pre="It is FDA-approved for the treatment of HIV-associated cytomegalo and" exact="herpes" post="simplex virus infections in humans [67]. Foscarnet is usually"/>
 <result pre="for the treatment of HIV-associated cytomegalo and herpes simplex virus" exact="infections" post="in humans [67]. Foscarnet is usually administered intravenously by"/>
 <result pre="usually administered intravenously by continuous intravenous infusion because of its" exact="short" post="half-life, which has also been demonstrated in cats [68]."/>
 <result pre="in both humans and cats. It also is toxic to" exact="epithelial" post="cells and mucous membranes, resulting in gastrointestinal side effects"/>
 <result pre="chelates various cations, which can lead to hypocalcemia, hypomagnesemia, and" exact="hypokalemia" post="[69,70]. In vitro, foscarnet has been shown to be"/>
 <result pre="activity against a variety of DNA and RNA viruses [71]." exact="Systemic" post="administration of ribavirin is limited in cats because of"/>
 <result pre="DNA and RNA viruses [71]. Systemic administration of ribavirin is" exact="limited" post="in cats because of side effects [72]. Sequestration of"/>
 <result pre="toxic effect on bone marrow, primarily on megakaryocytes, resulting in" exact="thrombocytopenia" post="and hemorrhage. With prolonged ribavirin treatment or at higher"/>
 <result pre="by incorporating it into lecithin-containing liposomes and administering it at" exact="lower" post="doses was not successful [75]. Ribavirin is active against"/>
 <result pre="virus or to the cellular receptor, leading to inhibition of" exact="viral" post="cell-surface binding. Most of the receptor homologues/antagonists are highly"/>
 <result pre="essential co-receptors for HIV as well as for FIV during" exact="infection" post="of CD4+ lymphocytes [79,80]. By binding to CXCR4, bicyclams"/>
 <result pre="to the active site of the protease and therefore prevent" exact="viral" post="replication. Several PIs have been used for successful treatment"/>
 <result pre="successful treatment of HIV. Nevertheless, side effects and development of" exact="viral" post="resistance were found during treatment, and therefore additional compounds"/>
 <result pre="enzyme integrase catalyzes strand transfer (3′-end joining), which inserts both" exact="viral" post="DNA ends into a host cell chromosome during proviral"/>
 <result pre="genome and functions as a template for replication of the" exact="viral" post="genome, leading to the formation of new viruses [89]."/>
 <result pre="proviral DNA that is produced by reverse transcription of the" exact="viral" post="RNA genome [91]. Raltegravir Raltegravir is used as an"/>
 <result pre="in immune response modulation [95]. They can be divided into" exact="type I" post="and type II IFNs, both of which have antiviral"/>
 <result pre="modulation [95]. They can be divided into type I and" exact="type II" post="IFNs, both of which have antiviral properties. Type I"/>
 <result pre="and type II IFNs, both of which have antiviral properties." exact="Type I" post="IFNs, including IFN-α, IFN-β, and IFN-ω, are produced by"/>
 <result pre="IFN-β, and IFN-ω, are produced by virus-infected cells [94,96], whereas" exact="type II" post="IFN, consisting of only IFN-γ, is produced by activated"/>
 <result pre="with potent anti-viral properties that interfere with various stages of" exact="viral" post="replication [98]. Several studies suggest that retroviral protein synthesis"/>
 <result pre="is mainly related to interference with later stages of the" exact="viral" post="replication cycle such as virion assembly and release [94,99]."/>
 <result pre="virus from infected cells and aids in the clearance of" exact="virus infection" post="[97]. Human IFNs have been manufactured by recombinant DNA"/>
 <result pre="from infected cells and aids in the clearance of virus" exact="infection" post="[97]. Human IFNs have been manufactured by recombinant DNA"/>
 <result pre="the oropharyngeal area triggers a cascade of immunologic responses with" exact="systemic" post="effects [102,103,104]. RHuIFN-α has been shown to be active"/>
 <result pre="ill, naturally FIV-infected cats (50 U/kg applied to the oral" exact="mucosa" post="daily for seven days on alternating weeks for six"/>
 <result pre="infections) in a placebo-controlled, double-blinded study [106]. However, proviral and" exact="viral" post="loads were not monitored during thiat study and therefore"/>
 <result pre="α had indeed an effect on FIV, or rather on" exact="secondary" post="infections. 9.2. Feline Interferon-ω Recombinant feline interferon-ω (rFeIFN-ω), the"/>
 <result pre="study that investigated the effect of parenteral rFeIFN-ω against FIV" exact="infection" post="in 62 naturally FIV-infected cats (treated with 106 U/kg"/>
 <result pre="scores (e.g., oral lesions, coat appearance, body condition score, and" exact="ocular" post="discharge) after treatment. In addition, there was no significant"/>
 <result pre="in earlier studies suggests that rFeIFN-ω has an effect on" exact="secondary" post="infections rather than on FIV itself [94]. As there"/>
 <result pre="earlier studies suggests that rFeIFN-ω has an effect on secondary" exact="infections" post="rather than on FIV itself [94]. As there are"/>
 <result pre="The duration of treatment in many clinical trials was relatively" exact="short" post="and might have been inadequate for infections with a"/>
 <result pre="trials was relatively short and might have been inadequate for" exact="infections" post="with a long clinical course. In addition, it is"/>
 <result pre="grades used according to the European Advisory Board of Cat" exact="Diseases" post="(ABCD). Drug Efficacy In Vitro Efficacy in Vivo Author’s"/>
 <result pre="consecutive days) yes [105] no [100] likely ineffective IV SC" exact="intermediate" post="dose (105 U/kg q 24 h for 90 days)"/>
 <result pre="[105] yes [106] some efficacy (most likely through effect on" exact="secondary" post="infection) I Feline interferon-ω (IFN-ω) SC high dose 106"/>
 <result pre="some improvement of clinical signs (most likely through effect on" exact="secondary" post="infection) I PO intermediate dose 105 U/cat q 24"/>
 <result pre="signs (most likely through effect on secondary infection) I PO" exact="intermediate" post="dose 105 U/cat q 24 h for 90 consecutive"/>
 <result pre="yes [108] potentially some efficacy (most likely through effect on" exact="secondary" post="infection) III PO low dose 105 U/cat q 24"/>
 <result pre="yes [105] nd potentially effective (most likely through effect on" exact="secondary" post="infection) IV FIV, feline immunodeficiency virus; nd, not determined."/>
 <result pre="(most likely through effect on secondary infection) IV FIV, feline" exact="immunodeficiency" post="virus; nd, not determined. EBM, evidence based medicine [4,110]:"/>
 <result pre="designed, randomized controlled studies in the target species with spontaneous" exact="disease" post="in an experimental setting. EBM grade III = Data"/>
 <result pre="target species with spontaneous disease in an experimental setting. EBM" exact="grade III" post="= Data based on non-randomized clinical trials, multiple case"/>
 <result pre="multiple case series, other experimental studies, and dramatic results from" exact="uncontrolled" post="studies. EBM grade IV = Expert opinion, case reports,"/>
 <result pre="in other species, pathophysiological justification. References References 1.GleichS.E.KriegerS.HartmannK.Prevalence of feline" exact="immunodeficiency" post="virus and feline leukaemia virus among client-owned cats and"/>
 <result pre="justification. References References 1.GleichS.E.KriegerS.HartmannK.Prevalence of feline immunodeficiency virus and feline" exact="leukaemia" post="virus among client-owned cats and risk factors for infection"/>
 <result pre="feline leukaemia virus among client-owned cats and risk factors for" exact="infection" post="in germanyJ. Feline Med. Surg.20091198599210.1016/j.jfms.2009.05.01919616984 2.AddieD.D.DennisJ.M.TothS.CallananJ.J.ReidS.JarrettO.Long-term impact on a"/>
 <result pre="impact on a closed household of pet cats of natural" exact="infection" post="with feline coronavirus, feline leukaemia virus and feline immunodeficiency"/>
 <result pre="of pet cats of natural infection with feline coronavirus, feline" exact="leukaemia" post="virus and feline immunodeficiency virusVet. Rec.200014641942410.1136/vr.146.15.41910811262 3.LevyJ.CrawfordC.HartmannK.Hofmann-LehmannR.LittleS.SundahlE.ThayerV.2008 american association"/>
 <result pre="natural infection with feline coronavirus, feline leukaemia virus and feline" exact="immunodeficiency" post="virusVet. Rec.200014641942410.1136/vr.146.15.41910811262 3.LevyJ.CrawfordC.HartmannK.Hofmann-LehmannR.LittleS.SundahlE.ThayerV.2008 american association of feline practitioners’ feline"/>
 <result pre="discovery of HIVInt. J. Antimicrob. Agents20093330732010.1016/j.ijantimicag.2008.10.01019108994 6.HartmannK.Antiviral and immunomodulatory chemotherapyInfectious" exact="Diseases" post="of the Dog and Cat4th ed.GreeneC.E.Elsevier, SaundersSt Louis, MO,"/>
 <result pre="Cat4th ed.GreeneC.E.Elsevier, SaundersSt Louis, MO, USA20121024 7.AuwerxJ.EsnoufR.de ClercqE.BalzariniJ.Susceptibility of feline" exact="immunodeficiency" post="virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to"/>
 <result pre="SaundersSt Louis, MO, USA20121024 7.AuwerxJ.EsnoufR.de ClercqE.BalzariniJ.Susceptibility of feline immunodeficiency virus/human" exact="immunodeficiency" post="virus type 1 reverse transcriptase chimeras to non-nucleoside RT"/>
 <result pre="MO, USA20121024 7.AuwerxJ.EsnoufR.de ClercqE.BalzariniJ.Susceptibility of feline immunodeficiency virus/human immunodeficiency virus" exact="type 1" post="reverse transcriptase chimeras to non-nucleoside RT inhibitorsMol. Pharmacol.20046524425110.1124/mol.65.1.24414722257 8.MohammadiH.BienzleD.Pharmacological"/>
 <result pre="chimeras to non-nucleoside RT inhibitorsMol. Pharmacol.20046524425110.1124/mol.65.1.24414722257 8.MohammadiH.BienzleD.Pharmacological inhibition of feline" exact="immunodeficiency" post="virus (FIV)Viruses2012470872410.3390/v405070822754645 9.TresslerR.GodfreyC.NRTI backbone in HIV treatment: Will it"/>
 <result pre="transcriptase inhibitors, and protease inhibitors in the treatment of HIV" exact="infections" post="(AIDS)Adv. Pharmacol.20136731735823886005 11.HorwitzJ.P.ChuaJ.NoelM.Nucleosides. V. The monomesylates of 1-(2'-deoxy-b- d-lyxofuranosyl)thymineJ."/>
 <result pre="light for clinical treatment of AIDSNature19873264303470603 14.GobertJ.M.RemingtonK.M.ZhuY.Q.NorthT.W.Multiple-drug-resistant mutants of feline" exact="immunodeficiency" post="virus selected with 2',3'-dideoxyinosine alone and in combination with"/>
 <result pre="with 3'-azido-3'-deoxythymidineAntimicrob. Agents Chemother.19943886186410.1128/AAC.38.4.8618031060 15.HartmannK.DonathA.KraftW.AZT in the treatment of feline" exact="immunodeficiency" post="virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine"/>
 <result pre="vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline" exact="immunodeficiency" post="virus, and two drug-resistant pol gene mutantsAm. J. Vet."/>
 <result pre="drug-resistant pol gene mutantsAm. J. Vet. Res.20016258859410.2460/ajvr.2001.62.58811327469 18.RemingtonK.M.ChesebroB.WehrlyK.PedersenN.C.NorthT.W.Mutants of feline" exact="immunodeficiency" post="virus resistant to 3′-azido-3′-deoxythymidineJ. Virol.1991653083121845891 19.RemingtonK.M.ZhuY.Q.PhillipsT.R.NorthT.W.Rapid phenotypic reversion of"/>
 <result pre="resistant to 3′-azido-3′-deoxythymidineJ. Virol.1991653083121845891 19.RemingtonK.M.ZhuY.Q.PhillipsT.R.NorthT.W.Rapid phenotypic reversion of zidovudine-resistant feline" exact="immunodeficiency" post="virus without loss of drug-resistant reverse transcriptaseJ. Virol.1994686326377507182 20.SchwartzA.M.McCrackinM.A.SchinaziR.F.HillP.B.VahlenkampT.W.TompkinsM.B.HartmannK.Antiviral"/>
 <result pre="20.SchwartzA.M.McCrackinM.A.SchinaziR.F.HillP.B.VahlenkampT.W.TompkinsM.B.HartmannK.Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline" exact="immunodeficiency" post="virus in feline peripheral blood mononuclear cellsAm. J. Vet."/>
 <result pre="nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline" exact="peripheral" post="blood mononuclear cellsAm. J. Vet. Res.20147527328110.2460/ajvr.75.3.27324564313 21.SmithR.A.RemingtonK.M.LloydR.M.Jr.SchinaziR.F.NorthT.W.A novel Met-to-Thr"/>
 <result pre="mutation in the YMDD motif of reverse transcriptase from feline" exact="immunodeficiency" post="virus confers resistance to oxathiolane nucleosidesJ. Virol.199771235723629032372 22.SmithR.A.RemingtonK.M.PrestonB.D.SchinaziR.F.NorthT.W.A novel"/>
 <result pre="point mutation at position 156 of reverse transcriptase from feline" exact="immunodeficiency" post="virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and"/>
 <result pre="(-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineJ. Virol.199872233523409499094 23.SmythN.R.McCrackenC.GaskellR.M.CameronJ.M.CoatesJ.A.GaskellC.J.HartC.A.BennettM.Susceptibility in cell culture of feline" exact="immunodeficiency" post="virus to eighteen antiviral agentsJ. Antimicrob. Chemother.19943458959410.1093/jac/34.4.5897532645 24.Tanabe-TochikuraA.TochikuraT.S.BlakesleeJ.R.Jr.OlsenR.G.MathesL.E.Anti-human immunodeficiency"/>
 <result pre="feline immunodeficiency virus to eighteen antiviral agentsJ. Antimicrob. Chemother.19943458959410.1093/jac/34.4.5897532645 24.Tanabe-TochikuraA.TochikuraT.S.BlakesleeJ.R.Jr.OlsenR.G.MathesL.E.Anti-human" exact="immunodeficiency" post="virus (HIV) agents are also potent and selective inhibitors"/>
 <result pre="(HIV) agents are also potent and selective inhibitors of feline" exact="immunodeficiency" post="virus (FIV)-induced cytopathic effect: Development of a new method"/>
 <result pre="25.VahlenkampT.W.De RondeA.BalzariniJ.NaesensL.De ClercqE.van EijkM.J.HorzinekM.C.EgberinkH.F.(r-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline" exact="immunodeficiency" post="virus infectionAntimicrob. Agents Chemother.19953974674910.1128/AAC.39.3.7467793884 26.ZhuY.Q.RemingtonK.M.NorthT.W.Mutants of feline immunodeficiency virus"/>
 <result pre="of feline immunodeficiency virus infectionAntimicrob. Agents Chemother.19953974674910.1128/AAC.39.3.7467793884 26.ZhuY.Q.RemingtonK.M.NorthT.W.Mutants of feline" exact="immunodeficiency" post="virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidineAntimicrob. Agents Chemother.199640198319878878567 27.NorthT.W.NorthG.L.PedersenN.C.Feline immunodeficiency virus,"/>
 <result pre="of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidineAntimicrob. Agents Chemother.199640198319878878567 27.NorthT.W.NorthG.L.PedersenN.C.Feline" exact="immunodeficiency" post="virus, a model for reverse transcriptase-targeted chemotherapy for acquired"/>
 <result pre="27.NorthT.W.NorthG.L.PedersenN.C.Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for" exact="acquired" post="immune deficiency syndromeAntimicrob. Agents Chemother.19893391591910.1128/AAC.33.6.9152475068 28.HartmannK.DonathA.KraftW.Azt in the treatment"/>
 <result pre="virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune" exact="deficiency" post="syndromeAntimicrob. Agents Chemother.19893391591910.1128/AAC.33.6.9152475068 28.HartmannK.DonathA.KraftW.Azt in the treatment of feline"/>
 <result pre="deficiency syndromeAntimicrob. Agents Chemother.19893391591910.1128/AAC.33.6.9152475068 28.HartmannK.DonathA.KraftW.Azt in the treatment of feline" exact="immunodeficiency" post="virus infection: Part 2Feline Pract.1995231320 29.HartmannK.Feline immunodeficiency virus infection:"/>
 <result pre="treatment of feline immunodeficiency virus infection: Part 2Feline Pract.1995231320 29.HartmannK.Feline" exact="immunodeficiency" post="virus infection: An overviewVet. J.199815512313710.1016/S1090-0233(98)80008-79564266 30.AugustE.M.MarongiuM.E.LinT.S.PrusoffW.H.Initial studies on the"/>
 <result pre="of 3'-deoxythymidin-2'-ene (D4T): A potent and selective inhibitor of human" exact="immunodeficiency" post="virusBiochem. Pharmacol.1988374419442210.1016/0006-2952(88)90655-72849444 31.BabaM.PauwelsR.HerdewijnP.de ClercqE.DesmyterJ.VandeputteM.Both 2′,3′-dideoxythymidine and its 2',3'-unsaturated derivative"/>
 <result pre="2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human" exact="immunodeficiency" post="virus replication in vitroBiochem. Biophys. Res. Commun.198714212813410.1016/0006-291X(87)90460-83028398 32.BalzariniJ.KangG.J.DalalM.HerdewijnP.de ClercqE.BroderS.JohnsD.G.The"/>
 <result pre="and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human" exact="immunodeficiency" post="virusBiochem. Pharmacol.198736271327182443141 34.MartinJ.C.HitchcockM.J.de ClercqE.PrusoffW.H.Early nucleoside reverse transcriptase inhibitors for"/>
 <result pre="36.TavaresL.RonekerC.PostieL.de NoronhaF.Testing of nucleoside analogues in cats infected with feline" exact="leukemia" post="virus: A modelIntervirology19893026352540111 37.MitsuyaH.BroderS.Inhibition of the in vitro infectivity"/>
 <result pre="Sci. USA1986831911191510.1073/pnas.83.6.19113006077 38.MedlinH.K.ZhuY.Q.RemingtonK.M.PhillipsT.R.NorthT.W.Selection and characterization of a mutant of feline" exact="immunodeficiency" post="virus resistant to 2',3'-dideoxycytidineAntimicrob. Agents Chemother.1996409539578849258 39.ZhuY.AntonyJ.M.MartinezJ.A.GlerumD.M.BrusseeV.HokeA.ZochodneD.PowerC.Didanosine causes sensory"/>
 <result pre="feline immunodeficiency virus resistant to 2',3'-dideoxycytidineAntimicrob. Agents Chemother.1996409539578849258 39.ZhuY.AntonyJ.M.MartinezJ.A.GlerumD.M.BrusseeV.HokeA.ZochodneD.PowerC.Didanosine causes" exact="sensory neuropathy" post="in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic"/>
 <result pre="immunodeficiency virus resistant to 2',3'-dideoxycytidineAntimicrob. Agents Chemother.1996409539578849258 39.ZhuY.AntonyJ.M.MartinezJ.A.GlerumD.M.BrusseeV.HokeA.ZochodneD.PowerC.Didanosine causes sensory" exact="neuropathy" post="in an HIV/AIDS animal model: Impaired mitochondrial and neurotrophic"/>
 <result pre="to 2',3'-dideoxycytidineAntimicrob. Agents Chemother.1996409539578849258 39.ZhuY.AntonyJ.M.MartinezJ.A.GlerumD.M.BrusseeV.HokeA.ZochodneD.PowerC.Didanosine causes sensory neuropathy in an" exact="HIV/AIDS" post="animal model: Impaired mitochondrial and neurotrophic factor gene expressionBrain:"/>
 <result pre="Neurol.20071302011202310.1093/brain/awm14817616550 40.collab: FDAAntiretroviral Drugs Used in the Treatment of Human" exact="Immunodeficiency" post="Virus InfectionAvailable online: http://www.Fda.Gov/forpatients/illness/HIVAIDS/treatment/ucm118915.Htm(accessed on 14 July 2015) 41.AraiM.EarlD.D.YamamotoJ.K.Is"/>
 <result pre="on 14 July 2015) 41.AraiM.EarlD.D.YamamotoJ.K.Is AZT/3TC therapy effective against FIV" exact="infection" post="or immunopathogenesis?Vet. Immunol. Immunopathol.20028518920410.1016/S0165-2427(01)00426-311943320 42.RavichandranS.VeerasamyR.RamanS.KrishnanP.N.AgravalR.K.An overview on HIV-1 reverse"/>
 <result pre="9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and mdl 74,968] in cell cultures and murine" exact="sarcoma" post="virus-infected newborn nmri miceAntimicrob. Agents Chemother.1997416116169056002 46.BalzariniJ.NaesensL.SlachmuyldersJ.NiphuisH.RosenbergI.HolyA.SchellekensH.de ClercqE.9-(2-phosphonylmethoxyethyl)adenine (PMEA)"/>
 <result pre="ClercqE.9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian" exact="immunodeficiency" post="virus infection in Rhesus monkeysAIDS19915212810.1097/00002030-199101000-000032059358 47.HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI.ThefeldS.Use of two virustatica"/>
 <result pre="(PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency" exact="virus infection" post="in Rhesus monkeysAIDS19915212810.1097/00002030-199101000-000032059358 47.HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI.ThefeldS.Use of two virustatica (AZT, PMEA)"/>
 <result pre="effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus" exact="infection" post="in Rhesus monkeysAIDS19915212810.1097/00002030-199101000-000032059358 47.HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI.ThefeldS.Use of two virustatica (AZT, PMEA)"/>
 <result pre="cats with clinical symptomsVet. Immunol. Immunopathol.19923516717510.1016/0165-2427(92)90129-E1363008 48.EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.de ClercqE.HorzinekM.KoolenM.Suppression of feline" exact="immunodeficiency" post="virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenineProc. Natl. Acad. Sci."/>
 <result pre="with clinical symptomsVet. Immunol. Immunopathol.19923516717510.1016/0165-2427(92)90129-E1363008 48.EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.de ClercqE.HorzinekM.KoolenM.Suppression of feline immunodeficiency" exact="virus infection" post="in vivo by 9-(2-phosphonomethoxyethyl)adenineProc. Natl. Acad. Sci. USA1990873087309110.1073/pnas.87.8.30872158102 49.HartmannK.Clinical"/>
 <result pre="clinical symptomsVet. Immunol. Immunopathol.19923516717510.1016/0165-2427(92)90129-E1363008 48.EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.de ClercqE.HorzinekM.KoolenM.Suppression of feline immunodeficiency virus" exact="infection" post="in vivo by 9-(2-phosphonomethoxyethyl)adenineProc. Natl. Acad. Sci. USA1990873087309110.1073/pnas.87.8.30872158102 49.HartmannK.Clinical"/>
 <result pre="acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline" exact="immunodeficiency" post="virusJ. Acquir. Immune Deficiency Syndr. Hum. Retrovirol.19981712012810.1097/00042560-199802010-00004 51.KufferM.BalzariniJ.RolinskiB.GoebelF.ErfleV.GoldbergM.HartmannK.comparative investigation"/>
 <result pre="(FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virusJ. Acquir. Immune" exact="Deficiency" post="Syndr. Hum. Retrovirol.19981712012810.1097/00042560-199802010-00004 51.KufferM.BalzariniJ.RolinskiB.GoebelF.ErfleV.GoldbergM.HartmannK.comparative investigation of the efficacy of"/>
 <result pre="Ausgabe K, Kleintiere/Heimtiere1997256716779459835 52.PhilpottM.S.EbnerJ.P.HooverE.A.Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline" exact="immunodeficiency" post="virus using a quantitative polymerase chain reactionVet. Immunol. Immunopathol.19923515516610.1016/0165-2427(92)90128-D1337395"/>
 <result pre="and adverse effects of the antiviral compound plerixafor in feline" exact="immunodeficiency" post="virus-infected catsJ. Vet. Intern. Med./Am. Coll. Vet. Intern. Med.20122648349010.1111/j.1939-1676.2012.00904.x22551322"/>
 <result pre="ClercqE.Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human" exact="immunodeficiency" post="virus in different human cell systemsBiochem. Biophys. Res. Commun.199621933734110.1006/bbrc.1996.02348604988"/>
 <result pre="55.XiaQ.RadzioJ.AndersonK.S.Sluis-CremerN.Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by" exact="transient" post="kinetic analysesProtein Sci.2007161728173710.1110/ps.07282900717656585 56.DasK.MartinezS.E.BaumanJ.D.ArnoldE.HIV-1 reverse transcriptase complex with DNA"/>
 <result pre="reveals non-nucleoside inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric human" exact="immunodeficiency" post="virus type 1 and feline immunodeficiency virus reverse transcriptases:"/>
 <result pre="inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric human immunodeficiency virus" exact="type 1" post="and feline immunodeficiency virus reverse transcriptases: Role of the"/>
 <result pre="Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric human immunodeficiency virus type 1 and feline" exact="immunodeficiency" post="virus reverse transcriptases: Role of the subunits in resistance/sensitivity"/>
 <result pre="and chemotherapy-refractory prostate cancerUrology19995353554110.1016/S0090-4295(98)00544-510096380 59.BroderS.YarchoanR.CollinsJ.M.LaneH.C.MarkhamP.D.KleckerR.W.RedfieldR.R.MitsuyaH.HothD.F.GelmannE.et al.Effects of suramin on HTLV-III/LAV" exact="infection" post="presenting as Kaposi’s Sarcoma or AIDS-related complex: Clinical pharmacology"/>
 <result pre="59.BroderS.YarchoanR.CollinsJ.M.LaneH.C.MarkhamP.D.KleckerR.W.RedfieldR.R.MitsuyaH.HothD.F.GelmannE.et al.Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s" exact="Sarcoma" post="or AIDS-related complex: Clinical pharmacology and suppression of virus"/>
 <result pre="ClercqE.Suramin: A potent inhibitor of the reverse transcriptase of RNA" exact="tumor" post="virusesCancer Lett.1979892210.1016/0304-3835(79)90017-X92362 61.CoganD.C.CotterS.M.KitchenL.W.Effect of suramin on serum viral replication"/>
 <result pre="of RNA tumor virusesCancer Lett.1979892210.1016/0304-3835(79)90017-X92362 61.CoganD.C.CotterS.M.KitchenL.W.Effect of suramin on serum" exact="viral" post="replication in feline leukemia virus-infected pet catsAm. J. Vet."/>
 <result pre="Lett.1979892210.1016/0304-3835(79)90017-X92362 61.CoganD.C.CotterS.M.KitchenL.W.Effect of suramin on serum viral replication in feline" exact="leukemia" post="virus-infected pet catsAm. J. Vet. Res.198647223022323022623 62.AbkowitzJ.L.Retrovirus-induced feline pure"/>
 <result pre="65.O’DonnellB.P.DawsonN.A.WeissR.B.MyersC.E.JamesW.D.Suramin-induced skin reactionsArch. Dermatol.1992128757910.1001/archderm.1992.016801100850111531404 66.CrumpackerC.S.Mechanism of action of foscarnet against" exact="viral" post="polymerasesAm. J. Med.1992923S7S10.1016/0002-9343(92)90329-A 67.WangY.SmithK.P.Safety of alternative antiviral agents for"/>
 <result pre="viral polymerasesAm. J. Med.1992923S7S10.1016/0002-9343(92)90329-A 67.WangY.SmithK.P.Safety of alternative antiviral agents for" exact="neonatal" post="herpes simplex virus encephalitis and disseminated infectionJ. Pediatr. Pharmacol."/>
 <result pre="polymerasesAm. J. Med.1992923S7S10.1016/0002-9343(92)90329-A 67.WangY.SmithK.P.Safety of alternative antiviral agents for neonatal" exact="herpes" post="simplex virus encephalitis and disseminated infectionJ. Pediatr. Pharmacol. Ther.201419728210.5863/1551-6776-19.2.7225024666"/>
 <result pre="67.WangY.SmithK.P.Safety of alternative antiviral agents for neonatal herpes simplex virus" exact="encephalitis" post="and disseminated infectionJ. Pediatr. Pharmacol. Ther.201419728210.5863/1551-6776-19.2.7225024666 68.StrawJ.A.LooT.L.de VeraC.C.NelsonP.D.TompkinsW.A.BaiS.A.Pharmacokinetics of"/>
 <result pre="coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on experimental feline calicivirus" exact="infection" post="in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of ribavirin"/>
 <result pre="or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline" exact="infectious" post="peritonitisRes. Vet. Sci.19935516217210.1016/0034-5288(93)90076-R8235082 76.GreeneC.E.WatsonA.D.J.Antiviral drugsInfectious Diseases of the Dog"/>
 <result pre="of experimentally induced feline infectious peritonitisRes. Vet. Sci.19935516217210.1016/0034-5288(93)90076-R8235082 76.GreeneC.E.WatsonA.D.J.Antiviral drugsInfectious" exact="Diseases" post="of the Dog and Cat2nd ed.GreeneC.E.Elsevier SaundersSt. Louis, MO,"/>
 <result pre="orphan receptors, and herpesvirus-encoded receptors by diverse human and simian" exact="immunodeficiency" post="virusesJ. Virol.199771899990079371556 78.WillettB.J.HosieM.J.The role of the chemokine receptor CXCR4"/>
 <result pre="virusesJ. Virol.199771899990079371556 78.WillettB.J.HosieM.J.The role of the chemokine receptor CXCR4 in" exact="infection" post="with feline immunodeficiency virusMol. Membr. Biol.199916677210332739 79.WillettB.J.PicardL.HosieM.J.TurnerJ.D.AdemaK.ClaphamP.R.Shared usage of"/>
 <result pre="role of the chemokine receptor CXCR4 in infection with feline" exact="immunodeficiency" post="virusMol. Membr. Biol.199916677210332739 79.WillettB.J.PicardL.HosieM.J.TurnerJ.D.AdemaK.ClaphamP.R.Shared usage of the chemokine receptor"/>
 <result pre="of the chemokine receptor CXCR4 by the feline and human" exact="immunodeficiency" post="virusesJ. Virol.199771640764159261358 80.WellsT.N.ProudfootA.E.PowerC.A.MarshM.Chemokine receptors—The new frontier for AIDS researchChem."/>
 <result pre="antagonists of the human chemokine receptor CXCR4, potently inhibit feline" exact="immunodeficiency" post="virus replicationJ. Virol.1999736346635210400726 83.ScholsD.EsteJ.A.HensonG.de ClercqE.Bicyclams, a class of potent"/>
 <result pre="by amd3100, a CXCR4 antagonistBlood20031022728273010.1182/blood-2003-02-066312855591 85.NorelliS.El DakerS.D’OstilioD.MeleF.ManciniF.TagliaF.RuggieriA.CiccozziM.CaudaR.CiervoA.et al.Response of feline" exact="immunodeficiency" post="virus (FIV) to tipranavir may provide new clues for"/>
 <result pre="86.LeeT.LacoG.S.TorbettB.E.FoxH.S.LernerD.L.ElderJ.H.WongC.H.Analysis of the S3 and S3' subsite specificities of feline" exact="immunodeficiency" post="virus (FIV) protease: development of a broad-based protease inhibitor"/>
 <result pre="Acad. Sci. USA19989593994410.1073/pnas.95.3.9399448264 87.Huitron-ResendizS.de RozièresS.Sanchez-AlavezM.BühlerB.LinY.C.LernerD.L.HenriksenN.W.BurudiM.FoxH.S.TorbettB.E.et al.Resolution and prevention of feline" exact="immunodeficiency" post="virus-induced neurological deficits by treatment with the protease inhibitor"/>
 <result pre="induced by raltegravir resistance mutationsJ. Mol. Recognit.20092248049410.1002/jmr.97019623602 90.CattoriV.WeibelB.LutzH.Inhibition of feline" exact="leukemia" post="virus replication by the integrase inhibitor raltegravirVet. Microbiol.201115216516810.1016/j.vetmic.2011.03.03921570781 91.GreggsW.M.3rdClouserC.L.PattersonS.E.ManskyL.M.Discovery"/>
 <result pre="raltegravirVet. Microbiol.201115216516810.1016/j.vetmic.2011.03.03921570781 91.GreggsW.M.3rdClouserC.L.PattersonS.E.ManskyL.M.Discovery of drugs that possess activity against feline" exact="leukemia" post="virusJ. Gen. Virol.20129390090510.1099/vir.0.039909-022258856 92.TogamiH.ShimuraK.OkamotoM.YoshikawaR.MiyazawaT.MatsuokaM.Comprehensive in vitro analysis of simian"/>
 <result pre="virusJ. Gen. Virol.20129390090510.1099/vir.0.039909-022258856 92.TogamiH.ShimuraK.OkamotoM.YoshikawaR.MiyazawaT.MatsuokaM.Comprehensive in vitro analysis of simian retrovirus" exact="type 4" post="susceptibility to antiretroviral agentsJ. Virol.2013874322432910.1128/JVI.03208-1223365453 93.BoeschA.CattoriV.RiondB.WilliB.MeliM.L.RentschK.M.HosieM.J.Hofmann-LehmannR.LutzH.Evaluation of the effect"/>
 <result pre="Virol.20129390090510.1099/vir.0.039909-022258856 92.TogamiH.ShimuraK.OkamotoM.YoshikawaR.MiyazawaT.MatsuokaM.Comprehensive in vitro analysis of simian retrovirus type 4" exact="susceptibility to" post="antiretroviral agentsJ. Virol.2013874322432910.1128/JVI.03208-1223365453 93.BoeschA.CattoriV.RiondB.WilliB.MeliM.L.RentschK.M.HosieM.J.Hofmann-LehmannR.LutzH.Evaluation of the effect of short-term"/>
 <result pre="integrase inhibitor raltegravir (Isentress) on the course of progressive feline" exact="leukemia" post="virus infectionVet. Microbial.201517516717810.1016/j.vetmic.2014.10.03125500005 94.DomenechA.MiroG.ColladoV.M.BallesterosN.SanjoseL.EscolarE.MartinS.Gomez-LuciaE.Use of recombinant interferon omega in"/>
 <result pre="melanoma: Final results of a phase I–II study of the" exact="cancer" post="biotherapy research group and the mid-atlantic oncology programCancer1998821677168110.1002/(SICI)1097-0142(19980501)82:9&amp;lt;1677::AID-CNCR13&amp;gt;3.0.CO;2-19576288 96.GilS.LealR.O.DuarteA.McGahieD.SepulvedaN.SiborroI.CravoJ.CartaxeiroC.TavaresL.M.Relevance"/>
 <result pre="feline interferon omega for clinical improvement and reduction of concurrent" exact="viral" post="excretion in retrovirus infected cats from a rescue shelterRes."/>
 <result pre="antiviral response and virus countermeasuresJ. Gen. Virol.2000812341236410.1099/0022-1317-81-10-234110993923 98.GerlachN.GibbertK.AlterC.NairS.ZelinskyyG.JamesC.M.DittmerU.Anti-retroviral effects of" exact="type I" post="IFN subtypes in vivoEur. J. Immunol.20093913614610.1002/eji.20083831119130550 99.Gomez-LuciaE.ColladoV.M.MiroG.DomenechA.Effect of type-I"/>
 <result pre="in combination with zidovudine for the treatment of presymptomatic feline" exact="leukemia" post="virus-induced immunodeficiency syndromeAntimicrob. Agents Chemother.1990341749175610.1128/AAC.34.9.17492178336 101.CantellK.PyhalaL.Circulating interferon in rabbits"/>
 <result pre="with zidovudine for the treatment of presymptomatic feline leukemia virus-induced" exact="immunodeficiency" post="syndromeAntimicrob. Agents Chemother.1990341749175610.1128/AAC.34.9.17492178336 101.CantellK.PyhalaL.Circulating interferon in rabbits after administration"/>
 <result pre="oral natural human interferon alpha) in the management of HIV-1" exact="infection" post="and acquired immune deficiency syndrome (AIDS)East. Afr. Med. J.1990676470"/>
 <result pre="human interferon alpha) in the management of HIV-1 infection and" exact="acquired" post="immune deficiency syndrome (AIDS)East. Afr. Med. J.1990676470 104.TompkinsW.A.Immunomodulation and"/>
 <result pre="alpha) in the management of HIV-1 infection and acquired immune" exact="deficiency" post="syndrome (AIDS)East. Afr. Med. J.1990676470 104.TompkinsW.A.Immunomodulation and therapeutic effects"/>
 <result pre="in the management of HIV-1 infection and acquired immune deficiency" exact="syndrome" post="(AIDS)East. Afr. Med. J.1990676470 104.TompkinsW.A.Immunomodulation and therapeutic effects of"/>
 <result pre="use of interferon-alpha: Mechanism of actionJ. Interferon Cytokine Res.19991981782810.1089/10799909931332510476925 105.TanabeT.YamamotoJ.K.Feline" exact="immunodeficiency" post="virus lacks sensitivity to the antiviral activity of feline"/>
 <result pre="ifn-gammaJ. Interferon Cytokine Res.2001211039104610.1089/10799900131720516911798461 106.PedrettiE.PasseriB.AmadoriM.IsolaP.di PedeP.TeleraA.VescoviniR.QuintavallaF.PistelloM.Low-dose interferon-alpha treatment for feline" exact="immunodeficiency" post="virus infectionVet. Immunol. Immunopathol.200610924525410.1016/j.vetimm.2005.08.02016169599 107.De MariK.MaynardL.SanquerA.LebreuxB.EunH.M.Therapeutic effects of recombinant"/>
 <result pre="Immunopathol.200610924525410.1016/j.vetimm.2005.08.02016169599 107.De MariK.MaynardL.SanquerA.LebreuxB.EunH.M.Therapeutic effects of recombinant feline interferon-omega on feline" exact="leukemia" post="virus (FELV)-infected and FELV/feline immunodeficiency virus (FIV)-coinfected symptomatic catsJ."/>
 <result pre="recombinant feline interferon-omega on feline leukemia virus (FELV)-infected and FELV/feline" exact="immunodeficiency" post="virus (FIV)-coinfected symptomatic catsJ. Vet. Intern. Med./Am. Coll. Vet."/>
 <result pre="on feline leukemia virus (FELV)-infected and FELV/feline immunodeficiency virus (FIV)-coinfected" exact="symptomatic" post="catsJ. Vet. Intern. Med./Am. Coll. Vet. Intern. Med.20041847748210.1892/0891-6640(2004)18&amp;lt;477:TEORFI&amp;gt;2.0.CO;2 108.GilS.LealR.O.McGahieD.SepulvedaN.DuarteA.NizaM.M.TavaresL.Oral"/>
 <result pre="of viremia, proviral load and cytokine profile in naturally feline" exact="immunodeficiency" post="virus infected cats treated with two different protocols of"/>
</results>
